Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Advanced Melanoma

Journal Scan / Research · February 04, 2020

Tumor CD8+ T-Cell Infiltration and PD-L1+ Immune Cells Predict Improved DFS in BRAF V600E–Mutated Melanoma

Annals of Oncology


Additional Info

Annals of Oncology
Prognostic Impact of Baseline Tumour Immune Infiltrate on Disease-Free Survival in Patients With Completely Resected, BRAFv600 Mutation-Positive Melanoma Receiving Adjuvant Vemurafenib
Ann. Oncol 2020 Jan 01;31(1)153-159, PA Ascierto, KD Lewis, AM Di Giacomo, L Demidov, M Mandalà, I Bondarenko, C Herbert, A Mackiewicz, P Rutkowski, A Guminski, B Simmons, C Ye, G Hooper, MJ Wongchenko, GR Goodman, Y Yan, D Schadendorf

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading